Anocca signs licensing deal for EmendoBio’s gene-editing tech
Pharmaceutical Technology
MARCH 15, 2024
Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.
Gene Editing Related Topics 
FDA approves Vertex’s gene-edited therapy for beta thalassemia
Pharmaceutical Technology
JANUARY 17, 2024
The US FDA has approved Vertex's CASGEVY, a gene-edited cell therapy, to treat transfusion-dependent beta thalassemia.
Gene Editing 
245
245 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Moderna ends gene editing alliance with Metagenomi
Bio Pharma Dive
MAY 2, 2024
Metagenomi said the companies’ decision to part ways followed a “strategic prioritization” undertaken by Moderna, which has made several investments in gene editing research in recent years.
Gene Editing 157
157 
Sanofi expands research deal with gene editing startup Scribe
Bio Pharma Dive
JULY 17, 2023
Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.
Gene Editing 237
237 
Pfizer expands into gene editing with Beam research deal
Bio Pharma Dive
JANUARY 10, 2022
Pfizer's work with mRNA vaccines led it explore other applications of the technology, resulting in a multi-year partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases.
Gene Editing 363
363 
Vertex aligns with another CRISPR gene editing startup
Bio Pharma Dive
OCTOBER 26, 2021
A new alliance with Mammoth Biosciences marks the latest evidence of Vertex's interest in gene editing, which has already been the focus of multiple deals with emerging biotechs.
Gene Editing 341
341 
FDA sets out advice to developers of gene editing medicines
Bio Pharma Dive
MARCH 16, 2022
Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing.
Gene Editing 328
328 
Gene editing biotech Homology hits reset and seeks a sale
Bio Pharma Dive
JULY 28, 2023
The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.
Gene Editing 246
246 
FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug
Bio Pharma Dive
MARCH 2, 2023
The announcement, which follows recent regulatory setbacks for some of Intellia’s peers, is a “big win” for the gene editing field, according to one analyst.
Gene Editing 307
307 
July 31, 2024: Gene Editing Therapies and Population Health, in This Week’s PCT Grand Rounds
Rethinking Clinical Trials
JULY 31, 2024
Adrian Hernandez In this Friday’s PCT Grand Rounds, Adrian Hernandez of Duke University will present “Precision Health to Population Health: Opportunities and Challenges for Gene Editing Therapies.” ” The Grand Rounds session will be held on Friday, August 2, 2024, at 1:00 pm eastern. Join the online meeting.
Gene Editing 147
147 
Vertex, Verve team up to develop a gene editing drug for liver disease
Bio Pharma Dive
JULY 20, 2022
The deal, which is worth $60 million upfront, broadens Vertex’s reach into gene editing and expands Verve’s research beyond heart disease.
Gene Editing 332
332 
Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods
Bio Pharma Dive
FEBRUARY 1, 2022
The collaboration with GenEdit, a South San Francisco startup developing new ways of delivering gene editing tools into the body, dates back to December 2020, but has recently begun to advance.
Gene Editing 332
332 
Regeneron and Mammoth team up to develop gene editing therapies
Pharmaceutical Technology
APRIL 26, 2024
Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.
Gene Editing 130
130 
Intellia, with first results, delivers a 'landmark' for CRISPR gene editing
Bio Pharma Dive
JUNE 26, 2021
Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research.
Gene Editing 363
363 
Moderna, teaming with a startup, wades further into gene editing
Bio Pharma Dive
NOVEMBER 2, 2021
The biotech has identified gene editing as a natural fit for the technology it uses to deliver its vaccines and drugs. A deal with Metagenomi, a startup backed by Bayer, will further those ambitions.
Gene Editing 313
313 
Caribou raises $304M in one of gene editing's most lucrative IPOs
Bio Pharma Dive
JULY 23, 2021
The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam.
Gene Editing 339
339 
CRISPR gene editing on human embryos may have dangerous consequences, says new study
Pharmaceutical Technology
JUNE 29, 2023
Experts warn caution around CRISPR gene editing technology on human embryos as it may have dangerous consequences.
Gene Editing 246
246 
Intellia, expanding in gene editing, buys startup Rewrite for $45M
Bio Pharma Dive
FEBRUARY 3, 2022
Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.
Gene Editing 270
270 
Beam, Apellis partner in deal to expand gene editing's reach
Bio Pharma Dive
JUNE 30, 2021
The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing.
Gene Editing 313
313 
Verve Therapeutics gets grant for gene editing compositions to lower ldl cholesterol levels
Pharmaceutical Technology
AUGUST 22, 2024
Discover how Verve Therapeutics' new patent for gene editing targeting the PCSK9 gene could revolutionize LDL cholesterol treatment and combat cardiovascular disease.
Gene Editing 100
100 
Gene editing biotech Verve to raise $267M in large IPO
Bio Pharma Dive
JUNE 17, 2021
Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year.
Gene Editing 301
301 
The Significance of the MHRA Approval and Upcoming FDA Review of the First Gene Editing Treatment
Worldwide Clinical Trials
NOVEMBER 27, 2023
Casgevy, the commercial product formerly known as exa-cel, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a laboratory, with the modified cells then infused back into the patient after conditioning treatment to prepare the bone marrow.
Gene Editing 189
189 
Gene editing biotechs face new uncertainty after CRISPR patent ruling
Bio Pharma Dive
MARCH 2, 2022
A federal patent board ruled Broad Institute scientists were first to a key gene editing advance, weakening the patent position of Intellia and CRISPR Therapeutics, which hold licenses through the University of California.
Gene Editing 205
205 
'The Top Line': Gene editing's next act
Fierce Pharma
FEBRUARY 16, 2024
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia.
Gene Editing 115
115 
Regeneron expands in gene editing with Mammoth deal
Bio Pharma Dive
APRIL 25, 2024
“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
Gene Editing 307
307 
Moderna partners with Life Edit for mRNA gene editing therapies
Pharmaceutical Technology
FEBRUARY 23, 2023
Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. The post Moderna partners with Life Edit for mRNA gene editing therapies appeared first on Pharmaceutical Technology.
Gene Editing 147
147 
Experts weigh medical advances in gene-editing with ethical dilemmas
NPR Health - Shots
MARCH 6, 2023
The last time this summit convened in 2018, the world was shocked to hear a scientist had created the first gene-edited babies. He was condemned, but gene-editing has continued, with some success. Image credit: Anthony Wallace/AFP via Getty Images)
Gene Editing 133
133 
Welcome to the Brave New World of CRISPR Gene Editing
BioSpace
NOVEMBER 16, 2023
s conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel raises some potential safety concerns with the risk of off-target effects.
Gene Editing 108
108 
Sickle cell patient's success with gene editing raises hopes and questions
NPR Health - Shots
MARCH 16, 2023
A Mississippi woman's life has been transformed by a treatment for sickle cell disease with the gene-editing technique CRISPR. All her symptoms from a disease once thought incurable have disappeared. Image credit: Orlando Gili for NPR)
Gene Editing 145
145 
AstraZeneca to acquire gene editing biotech LogicBio
Bio Pharma Dive
OCTOBER 3, 2022
Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.
Gene Editing 356
356 
Prime to narrow gene editing research as it strikes deal with Bristol Myers
Bio Pharma Dive
SEPTEMBER 30, 2024
The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.
Gene Editing 184
184 
Chances of eliminating HIV infection increased by novel dual gene-editing approach
Medical Xpress
MAY 1, 2023
Gene-editing therapy aimed at two targets—HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells—can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) shows.
Gene Editing 124
124 
Gene editing: beyond the hype
pharmaphorum
JANUARY 29, 2021
Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers. That would just slow the whole field down.
Gene Editing 145
145 
Gene editing & CRISPR: Advances in applications and opportunity
Drug Discovery World
FEBRUARY 22, 2024
This eBook explores the latest innovations in gene editing and CRISPR, the possibilities of new editing techniques and where the greatest potential for the technology might lie in the future. The post Gene editing & CRISPR: Advances in applications and opportunity appeared first on Drug Discovery World (DDW).
Gene Editing 52
52 
Cellectis rockets on gene-editing alliance with AstraZeneca
pharmaphorum
NOVEMBER 1, 2023
Cellectis rockets on gene-editing alliance with AstraZeneca Phil.Taylor Wed, 01/11/2023 - 12:05 Bookmark this
Gene Editing 101
101 
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
Bio Pharma Dive
DECEMBER 8, 2023
In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.
Gene Editing 349
349 
A gene editing biotech’s struggles end with reverse merger
Bio Pharma Dive
NOVEMBER 15, 2023
Since halting work on a sickle cell treatment early this year, Graphite Bio has laid off staff, shed assets and, now, agreed to be subsumed via a merger with Lenz Therapeutics.
Gene Editing 273
273 
Moderna inks another gene editing deal
Bio Pharma Dive
FEBRUARY 22, 2023
The messenger RNA specialist said Wednesday it is teaming up with Life Edit Therapeutics to develop therapies that can modify genes “in vivo.”
Gene Editing 261
261 
Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia
Fierce Pharma
JANUARY 16, 2024
Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.
Gene Editing 113
113 
JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's and Pfizer's deep pockets
Bio Pharma Dive
JANUARY 12, 2021
Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking.
Gene Editing 189
189 
FDA sets decision dates for Vertex, CRISPR gene editing drug
Bio Pharma Dive
JUNE 9, 2023
The regulator will issue separate verdicts on the pioneering treatment’s use in sickle cell disease and beta thalassemia, with the first expected late this year.
Gene Editing 326
326 
Gene-editing firm Prime Medicine files $140m public offer
pharmaphorum
FEBRUARY 15, 2024
Gene-editing biotech Prime Medicine has priced its IPO, hoping to raise $140m to advance its pipeline of one-shot therapies for severe genetic disorders.
Gene Editing 64
64 
New eBook: What does the future hold for gene editing & CRISPR?
Drug Discovery World
FEBRUARY 22, 2024
Following the first regulatory approval of a CRISPR-based drug in late 2023, over ten years since the CRISPR-Cas9 system was elucidated, there is considerable optimism about the future potential for gene editing technologies. appeared first on Drug Discovery World (DDW).
Gene Editing 52
52 
Gene editing biotech Metagenomi pulls off nearly $94M IPO
Bio Pharma Dive
FEBRUARY 8, 2024
The company is one of three preclinical biotechs to successfully go public since last summer, but it pulled in significantly less than others who’ve debuted with more advanced medicines.
Gene Editing 205
205 
Let's personalize your content